Q3 2023 Earnings Estimate for Ionis Pharmaceuticals, Inc. Issued By William Blair (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) – Investment analysts at William Blair cut their Q3 2023 earnings estimates for Ionis Pharmaceuticals in a report issued on Wednesday, August 9th. William Blair analyst M. Minter now expects that the company will post earnings of ($0.95) per share for the quarter, down from their previous forecast […]

Related Keywords

United States ,Nevada ,William Blair ,Patrickr Oneil ,Banque Cantonale Vaudoise ,Allenem Diaz ,Ionis Pharmaceuticals ,Securities Exchange Commission ,Nasdaq ,Ionis Pharmaceuticals Inc ,Almanack Investment Partners ,News Ratings For Ionis Pharmaceuticals Daily ,Barclays ,Nevada Inc ,Quilter Plc ,Insider Transactions At Ionis Pharmaceuticals ,Citigroup ,Needham Company ,Whittier Trust Co ,Ionis Pharmaceuticals Stock Performance ,Free Report ,Ionis Pharmaceutical ,Get Free Report ,Investment Partners ,Cantonale Vaudoise ,Director Allene ,Exchange Commission ,Ionis Pharmaceuticals Daily ,Nasdaq Ions ,Lions ,Medical ,46433010 ,Earnings Estimates ,